17 min listen
Keeping Your ESCHELONs Straight With Drs. Brad Kahl and Steven Horwitz
FromThe Hematologist
ratings:
Length:
17 minutes
Released:
Mar 5, 2019
Format:
Podcast episode
Description
In this podcast, Contributing Editor Dr. Brad Kahl has a conversation with Dr. Steven Horwitz. They discuss Dr. Kahl's Diffusion article from the March/April 2019 issue of The Hematologist. The article titled, "Keeping Your ESCHELONs Straight," covers the ESCHELON-2 study, a trial that used a "repeal and replace" strategy, eliminating vincristine from the experimental regimen and substituting in brentuximab vedotin to treat CD30+ T-cell lymphoma. You can find his Diffusion article online at www.hematology.org/Thehematologist/Diffusion/9387.aspx.
Dr. Steven Horwitz conflicts of interest include: He has received grants and research support from ADCT Therapeutics, Aileron, Celgene, Forty-Seven, Infinity/Verastem, Kyowa-Hakka-Kirin, Millenium/Takeda, Seattle Genetics and Trillipum, and is a consultant for ADCT Therapeutics, Aileron, Corvus, Forty-Seven, Innate Pharma, Kyowa-Hakka, Kirin, Takeda, Miragen, Mundipharma, Portola, Seattle Genetics, Beigene, Affimed, and Verastem.
Music: "Jellyfish in Space" Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
Dr. Steven Horwitz conflicts of interest include: He has received grants and research support from ADCT Therapeutics, Aileron, Celgene, Forty-Seven, Infinity/Verastem, Kyowa-Hakka-Kirin, Millenium/Takeda, Seattle Genetics and Trillipum, and is a consultant for ADCT Therapeutics, Aileron, Corvus, Forty-Seven, Innate Pharma, Kyowa-Hakka, Kirin, Takeda, Miragen, Mundipharma, Portola, Seattle Genetics, Beigene, Affimed, and Verastem.
Music: "Jellyfish in Space" Kevin MacLeod (incompetech.com). Licensed under Creative Commons: By Attribution 3.0 creativecommons.org/licenses/by/3.0/
Released:
Mar 5, 2019
Format:
Podcast episode
Titles in the series (100)
Navigating Future Challenges in Lymphoma: The strategic roadmap developed at the original ASH Meeting on Lymphoma Biology held in August 2014 was recently published in Blood. To continue this important conversation, Dr. Ann LaCasce (Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA by The Hematologist